Friday, July 10, 2026

Drug profile · INN

sevelamer hydrochloride

sevelamer hydrochloride (TASERMITY) is a phosphate sequestering agent. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: unknown Various (V03) V03AE02
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — sevelamer hydrochloride
US status
approved
Class
Various (V03)
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

sevelamer hydrochloride (TASERMITY) is a phosphate sequestering agent. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sevelamer hydrochloride
Brand TASERMITY
Mechanism Phosphate sequestering agent
Target Phosphate
Therapeutic class Various (V03)
Route ORAL
Formulation CAPSULE
ATC code V03AE02

Mechanism of action

Phosphate sequestering agent

Primary target: Phosphate

Approval history

Authority Status Date
FDA approved
EMA unknown

Pipeline programs

  1. sevelamer hydrochloride Unknown · University of Hong · Endstage Renal Disease

Related & competitor drugs

  1. alendronate sodium Farnesyl diphosphate synthase inhibitor
  2. besilesomab Various (V09)
  3. calcium acetate Phosphate sequestering agent
  4. deferasirox Various (V03)
  5. ferric citrate Phosphate sequestering agent
  6. ferric citrate coordination complex Various (V03)

Frequently asked questions

What is sevelamer hydrochloride?

sevelamer hydrochloride (TASERMITY) is a phosphate sequestering agent. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sevelamer hydrochloride?

TASERMITY is a marketed brand name for sevelamer hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sevelamer hydrochloride?

sevelamer hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.